MedTrace Logo

Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation

NCT01919450 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2018-08-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the consistency of quantitative peak stress myocardial blood flow and myocardial blood flow reserve following a 10 second, 1 minute, 2 minute or 4 minute delay in beginning the rubidium-82 infusion post-Lexiscan (regadenoson) injection. It is anticipated that there will be no or minimal difference between the four delay times.

Conditions

  • Myocardial Blood Flow Reserve

Interventions

DRUG

Regadenoson

Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.

RADIATION

Rubidium-82

Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.

Sponsors & Collaborators

  • Timothy M. Bateman, MD

    lead INDUSTRY

Principal Investigators

  • Timothy M Bateman, MD · Cardiovascular Imaging Technologies

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01919450 on ClinicalTrials.gov